Fuzapladib Sodium Injection for Dogs

Brenda Z is the fuzapladib-sodium product named on the photograph. Japan’s official veterinary reference identifies a freeze-dried injection preparation for improvement of clinical signs in dogs during acute pancreatitis.

Ingredient background in pancreatitis care

Fuzapladib is described in reference product information as an inhibitor of leukocyte function-associated antigen-1 activation, a pathway involved in inflammatory-cell activity. The medicine belongs to a veterinary pancreatitis-care plan; the clinical team assesses the dog and other supportive treatment.

Four milligrams of powder per vial

The Japanese Brenda Z reference specifies 4 mg of fuzapladib sodium on an anhydrous basis per freeze-dried vial. This is drug content, not a 4 mL ready-to-use liquid fill. The US PANOQUELL-CA1 reference describes a separate 14 mg vial.

Veterinary preparation and administration

Preparation and intravenous administration are carried out within the professional treatment plan. The Japanese label calls for preparation at the time of use and no carry-over of leftover prepared product to the next day. Product-page information is not a home-reconstitution guide.

Keep the market label with the product

Identify Brenda Z and the full vial/box specification when enquiring. Similar ingredient names do not make different market products identical in vial content, diluent or handling instructions.